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Conclusions: Rate of MACEs was significantly lower in the EES group when compared
with the SES, PES, and ZES groups, mainly due to the lower rate of TLR during the
3-year follow-up.
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Background: Implantation of drug-eluting stents in long coronary artery lesions is
associated with a higher risk for restenosis and stent thrombosis related to the need for
multiple and overlapping stents. The Resolute zotarolimus-eluting stent (R-ZES) is
manufactured in a 38 mm length to accommodate longer lesions but clinical data to
demonstrate efficacy and safety of the longer stent have not been reported.
Methods: A substudy of 2 prospective, multicenter clinical trials; RESOLUTE–US and
RESOLUTE-Asia enrolled patients with de novo coronary artery lesions amenable to
treatment with the 38-mm-length R-ZES. The target lesion had to be  35 mm long and
the primary endpoint was target lesion failure (TLF) defined as the composite of cardiac
death, target vessel myocardial infraction (TVMI), or clinically-driven target lesion revascu-
larization (TLR) by percutaneous or surgical methods. The rate of TLF at 1 year was compared
to a performance goal of 19.0% based on literature suggesting an expected TLF rate of 15.1%.
All patients were prescribed dual antiplatelet therapy for a minimum of 6 months.
Results: There were 223 patients treated with a 38 mm R-ZES; mean age was 61 years,
78.9% were men, 44.6% were white, 3.6% were black, and 50.9% were Asian. Prior PCI
was noted in 27.4% of patients, 37.7% had diabetes mellitus and 53.8% had multivessel
disease. Lesions were located in the LAD (52.0%), LCX (20.2%) and RCA (44.4%) and
3.4% were moderately or severely torturous. TIMI flow was 0 or 1 in 6.1% of lesions and
47.9% were branch vessel disease with mean sidebranch stenosis of 30.4%; 91.2% were
lesion class B2/C. The primary endpoint was met with a 12-month TLF rate of 4.5%
(upper one-sided 95% confidence interval 7.5%). Rates of cardiac death, TVMI, and TLR
at 12 months were 0.9%, 3.6%, and 1.4% respectively. Early stent thrombosis (30 days)
was 0.9% and there were no stent thrombosis events after 30 days.
Conclusions: At 12 months the rate of TLF was significantly less than the performance
goal of 19% and clinical events rates were low with no late stent thrombosis. The 38 mm
length R-ZES was safe and effective in this selected population of long lesion patients.
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Background: Higher levels of high-density lipoprotein cholesterol (HDL-C) have been
associated with decreased cardiovascular risk in epidemiologic studies, although a causal
role is in question. Dysfunctional HDL has been identified in humans with metabolic
syndrome (MSx) or coronary artery disease (CAD). Additionally, current determinations
of HDL-C may not correlate with the true anti-atherosclerotic properties, casting doubts
on its prognostic value. Therefore, the significance of HDL-C on the outcome of patients
with CAD requiring percutaneous coronary intervention (PCI) is unclear.
Methods: Patients treated with PCI from 01/2004 to 12/2011 were prospectively
enrolled. The lipid panel of those on statin therapy prior to PCI and who had attained
low-density lipoprotein cholesterol (LDL-C) 100 mg/dl was analyzed. Major adverse
cardiac events (MACE), including all-cause death, Q-wave myocardial infarction, and
target vessel revascularization at 1 year were evaluated in relation to the lipid profile at the
time of index PCI. Multivariable Cox proportional hazards regression was employed for
the entire cohort and for the subgroup of patients with diabetes mellitus (DM) or MSx.
Results: 2759 patients were included. The population’s mean age was 66 years and 68%
was male. 53% had a history of CAD, 39.8% had DM and 42.5% had MSx. At 1-year
follow-up, a total of 279 patients (10.1%) experienced MACE. Death occurred in 5.2% of
the population. HDL-C after adjustment for baseline characteristics did not demonstrate
an independent association with MACE in either the main population or the subgroup
with MSx (HR 1.00, 95% CI 0.99-1.01, p0.98 and HR 1.00, 95% CI 0.99-1.01, p0.93,
respectively). However, the evaluation of non-HDL levels at the time of PCI demonstrated
a trend for the subgroup of patients with DM or MSx (HR 0.99, 95% CI 0.99-1.00,
p0.07).
Conclusions: In patients treated with statin therapy for CAD, in whom an LDL-C level
100 mg/dl has been achieved at the time of PCI; HDL-C did not independently correlate
with MACE at 1 year. These data suggest that HDL-C for patients on statin therapy and
controlled LDL may not be an effective biomarker for future clinical events.
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Background: There are major differences in the structural design of currently available
coronary stents. Differences in radial forces have been reported between the different stent
platforms, but it is still unclear how stent material and strut design may affect stent
mechanical performances in clinical settings.
Methods: To evaluate coronary stent designs in a reproducible environment, we created
a compliant model of a focal coronary lesion, representing a 50% reduction in lumen
diameter. The stents evaluated were the Cobalt Chromium (CoCr) Xience V (Abbott
Vascular) and Integrity (Medtronic), 316L Stainless Steel (316L SS) Taxus Liberte
(Boston Scientific) and BioMatrix Flex (Biosensors Int.), and the Platinium Chromium
(PtCr) Promus Element (Boston Scientific). The 3.0 stents (n14) were deployed across
the model lesion at their Nominal Pressure (NP). Minimal Lumen Area (MLA), residual
% area stenosis and strut apposition were assessed at NP from micro-CT. After NP
assessment, the same 3.0 delivery balloon was then inflated at 18 ATM to evaluate impact
of deployment pressure on plaque recoil and residual stenosis. A total of 28 experiments
were performed.
Results: MLA was significantly increased with pressure deployment: from 5.0  0.5
mm2 at NP to 6.8  0.1 mm2 with 18 ATM dilatation (p0.001). This transposed in a
residual area stenosis reducing from an average of 23.7 % at NP to only -1.3 % (relative
to the reference vessel area) at 18 ATM (p0.0009). Higher pressure also elimated the
risk of mallaposed strut from a maximal cross-sectional rate of malapposed strut observed
of 25.6 % at NP compared to virtually zero malapposition at 18 ATM pressure. At NP,
CoCr stents resulted in overall higher MLA and lower residual stenosis than 316L SS and
PtCr stents, MLA was respectively 5.4 mm2 for CoCr, 4.9 mm2 for 316L SS and 5.0
mm2 for PtCr (p0.0001). Such differences were markedly eliminated with higher
pressure inflation: at 18 ATM, MLA was respectively 6.7 mm2 for CoCr, 6.6 mm2 for
316L SS and 6.8 mm2 for PtCr.
Conclusions: Initial results with 5 different DES designs underline the importance of
deployment pressure in the overall ability of a stent to scaffold a lesion and restore lumen
area.
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